Enzymes as targets for drug design:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
San Diego u.a.
Acad. Press
1989
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII, 267 S. Ill. |
| ISBN: | 0125440308 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV004045277 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 900921s1989 a||| |||| 10||| engod | ||
| 020 | |a 0125440308 |9 0-12-544030-8 | ||
| 035 | |a (OCoLC)20669818 | ||
| 035 | |a (DE-599)BVBBV004045277 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-355 | ||
| 050 | 0 | |a QP601.5 | |
| 082 | 0 | |a 615.7 |2 20 | |
| 084 | |a VK 8708 |0 (DE-625)147548:261 |2 rvk | ||
| 245 | 1 | 0 | |a Enzymes as targets for drug design |c ed. by Michael G. Palfreyman ... |
| 264 | 1 | |a San Diego u.a. |b Acad. Press |c 1989 | |
| 300 | |a XIII, 267 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Antienzymes | |
| 650 | 7 | |a Enzymen |2 gtt | |
| 650 | 4 | |a Enzymes | |
| 650 | 7 | |a Geneesmiddelen |2 gtt | |
| 650 | 4 | |a Médicaments - Conception | |
| 650 | 4 | |a Drug Design |v Congresses | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 4 | |a Enzyme Inhibitors |x therapeutic use |v Congresses | |
| 650 | 4 | |a Enzyme inhibitors | |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Enzyminhibitor |0 (DE-588)4152479-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
| 689 | 1 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Palfreyman, Michael G. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002531024&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-002531024 | ||
Datensatz im Suchindex
| _version_ | 1804118273867907072 |
|---|---|
| adam_text | 3 ENZYMES AS TARGETS FOR DRUG DESIGN EDITED BY MICHAEL G. PALFREY MAN
MERRELL DOW RESEARCH INSTITUTE CINCINNATI, OHIO PETER P. MCCANN MERRELL
DOW RESEARCH INSTITUTE CINCINNATI, OHIO WALTER LOVENBERG MERRELL DOW
RESEARCH INSTITUTE STRASBOURG, FRANCE. JOSEPH ^||FEMPLE, JR. MERRELL DOW
PHARMACEUTICALS, INC. CINCINNATI* OH,IP - - ALBERT SJC|EI;DSMA;
MERRELL DOW RESEARCH INSTITUTE CINCINNATI, OHIO ACADEMIC PRESS, INC.
HARCOURT BRACE JOVANOVICH, PUBLISHERS SAN DIEGO NEW YORK BOSTON LONDON
SYDNEY TOKYO TORONTO CONTENTS CONTRIBUTORS VII PREFACE XI 1. ENZYME
INHIBITORS AS DRUGS 1 J. RICHARD CROUT 2. BIOGENESIS OF
PHOSPHATIDYLINOSITOL GLYCOSYL MEMBRANE PROTEINS AND THEIR SIGNIFICANCE 5
SIDNEY UDENFRIEND 3. STRUCTURE AND CATALYTIC FUNCTION OF ADP-RIBOSE
POLYMERASE (ADPRT), A TARGET SITE FOR DRUGS INHIBITING MALIGNANT GROWTH
11 ERNEST KUN 4. MODULATION OF THE DOPAMINERGIC SYSTEM IN CARDIOVASCULAR
THERAPEUTICS 17 MICHAEL B. MURPHY, ALAN S. BASS, AND LEON I. GOLDBERG 5.
ALPHA-METHYLDOPA 31 WYBREN DE JONG AND PAUL VAN GIERSBERGEN 6.
CONSIDERING RECEPTOR NON-SPECIFICITY AS A FACTOR FOR DEVELOPING -EFFECT,
TISSUE AND RECEPTOR SPECIFIC AGENTS 45 KENNETH L. MELMON AND MANZOOR M.
KHAN 7. MECHANISM-BASED ENZYME INHIBITORS AS AN APPROACH TO DRUG DESIGN
59 PHILIPPE BEY 8. COFACTOR DEPENDENCY IN THE INHIBITION OF STEROID 5
ALPHA-REDUCTASE 85 BRIAN W. METCALF, DENNIS A. HOLT, AND MARK A. LEVY 9.
HYDROXYLASES AS TARGETS FOR DRUG DESIGN 101 WALTER LOVENBERG VI CONTENTS
10. ALPHA-FLUOROMETHYLTYROSINE, ALPHA-FLUOROMETHYLTRYPTOPHAN AND
BIOGENIC AMINE SYNTHESIS 121 MICHELJ. JUNG, JEAN-MARIE HORNSPERGER,
DANIEL SCHIRLIN, AND FRITZ GERHART 11. TYROSINE AND TRYPTOPHAN ANALOGUES
AS DUAL ENZYME-ACTIVATED INHIBITORS OF MONOAMINE OXIDASE 139 MICHAEL G.
PALFREYMAN, MONIQUE ZREIKA, AND IAN A. MCDONALD 12. INHIBITION OF
POLYAMINE BIOSYNTHESIS AND FUNCTION AS AN APPROACH TO DRUG DESIGN 157
ANTHONY E. PEGG, PETER P. MCCANN, AND ALBERT SJOERDSMA 13. CONCEPTS FOR
DERIVING SPECIFIC INHIBITORS OF POLYAMINE BIOSYNTHESIS* HUMAN LUNG
CANCER CELLS AS A MODEL SYSTEM 185 ROBERT A. CASERO, JR. AND STEPHEN B.
BAYLIN 14. THERAPEUTIC UTILITY OF SELECTED ENZYME-ACTIVATED IRREVERSIBLE
INHIBITORS 201 PAUL J. SCHECHTER AND ALBERT SJOERDSMA 15.
INTRA-BLOOD-BRAIN-BARRIER IGG SYNTHESIS IN HIV 211 WALLACE W.
TOURTELLOTTE, ELYSE SINGER, KARL SYNDULKO, PAUL SHAPSHAK, AND LIONEL
RESNICK 16. PROTEINASES IN THE FIBROSIS OF SYSTEMIC SCLEROSIS 219 E.
CARWILE LEROY AND M. BASHAR KAHALEH 17. THERAPEUTIC OPPORTUNITIES IN
EICOSANOID BIOSYNTHISIS 225 JOHN A. OATES 18. MAO AS A TARGET FOR DRUG
DESIGN: CLINICAL ISSUES 233 DONALD S. ROBINSON INDEX 259
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV004045277 |
| callnumber-first | Q - Science |
| callnumber-label | QP601 |
| callnumber-raw | QP601.5 |
| callnumber-search | QP601.5 |
| callnumber-sort | QP 3601.5 |
| callnumber-subject | QP - Physiology |
| classification_rvk | VK 8708 |
| ctrlnum | (OCoLC)20669818 (DE-599)BVBBV004045277 |
| dewey-full | 615.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7 |
| dewey-search | 615.7 |
| dewey-sort | 3615.7 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01999nam a2200541 c 4500</leader><controlfield tag="001">BV004045277</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">900921s1989 a||| |||| 10||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0125440308</subfield><subfield code="9">0-12-544030-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)20669818</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV004045277</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP601.5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.7</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VK 8708</subfield><subfield code="0">(DE-625)147548:261</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enzymes as targets for drug design</subfield><subfield code="c">ed. by Michael G. Palfreyman ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego u.a.</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">1989</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 267 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antienzymes</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Enzymen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzymes</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geneesmiddelen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments - Conception</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme Inhibitors</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme inhibitors</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palfreyman, Michael G.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002531024&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-002531024</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Aufsatzsammlung Konferenzschrift |
| id | DE-604.BV004045277 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T16:07:41Z |
| institution | BVB |
| isbn | 0125440308 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-002531024 |
| oclc_num | 20669818 |
| open_access_boolean | |
| owner | DE-12 DE-355 DE-BY-UBR |
| owner_facet | DE-12 DE-355 DE-BY-UBR |
| physical | XIII, 267 S. Ill. |
| publishDate | 1989 |
| publishDateSearch | 1989 |
| publishDateSort | 1989 |
| publisher | Acad. Press |
| record_format | marc |
| spelling | Enzymes as targets for drug design ed. by Michael G. Palfreyman ... San Diego u.a. Acad. Press 1989 XIII, 267 S. Ill. txt rdacontent n rdamedia nc rdacarrier Antienzymes Enzymen gtt Enzymes Geneesmiddelen gtt Médicaments - Conception Drug Design Congresses Drugs Design Enzyme Inhibitors therapeutic use Congresses Enzyme inhibitors Arzneimittel (DE-588)4003115-9 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Enzyminhibitor (DE-588)4152479-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content (DE-588)1071861417 Konferenzschrift gnd-content Enzyminhibitor (DE-588)4152479-2 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Arzneimittel (DE-588)4003115-9 s Palfreyman, Michael G. Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002531024&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Enzymes as targets for drug design Antienzymes Enzymen gtt Enzymes Geneesmiddelen gtt Médicaments - Conception Drug Design Congresses Drugs Design Enzyme Inhibitors therapeutic use Congresses Enzyme inhibitors Arzneimittel (DE-588)4003115-9 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Enzyminhibitor (DE-588)4152479-2 gnd |
| subject_GND | (DE-588)4003115-9 (DE-588)4143176-5 (DE-588)4152479-2 (DE-588)4143413-4 (DE-588)1071861417 |
| title | Enzymes as targets for drug design |
| title_auth | Enzymes as targets for drug design |
| title_exact_search | Enzymes as targets for drug design |
| title_full | Enzymes as targets for drug design ed. by Michael G. Palfreyman ... |
| title_fullStr | Enzymes as targets for drug design ed. by Michael G. Palfreyman ... |
| title_full_unstemmed | Enzymes as targets for drug design ed. by Michael G. Palfreyman ... |
| title_short | Enzymes as targets for drug design |
| title_sort | enzymes as targets for drug design |
| topic | Antienzymes Enzymen gtt Enzymes Geneesmiddelen gtt Médicaments - Conception Drug Design Congresses Drugs Design Enzyme Inhibitors therapeutic use Congresses Enzyme inhibitors Arzneimittel (DE-588)4003115-9 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Enzyminhibitor (DE-588)4152479-2 gnd |
| topic_facet | Antienzymes Enzymen Enzymes Geneesmiddelen Médicaments - Conception Drug Design Congresses Drugs Design Enzyme Inhibitors therapeutic use Congresses Enzyme inhibitors Arzneimittel Arzneimittelentwicklung Enzyminhibitor Aufsatzsammlung Konferenzschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002531024&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT palfreymanmichaelg enzymesastargetsfordrugdesign |